XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized…